Dunhill Financial’s Fate Therapeutics FATE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.54K Sell
2
-3,178
-100% -$8.22K ﹤0.01% 658
2026
Q2
$8.59K Hold
3,180
– – ﹤0.01% 610
2026
Q1
$3.82K Hold
3,180
– – ﹤0.01% 676
2025
Q4
$3.12K Hold
3,180
– – ﹤0.01% 672
2025
Q3
$4.01K Hold
3,180
– – ﹤0.01% 587
2025
Q2
$3.56K Hold
3,180
– – ﹤0.01% 590
2025
Q1
$2.51K Hold
3,180
– – ﹤0.01% 697
2024
Q4
$5.25K Hold
3,180
– – ﹤0.01% 529
2024
Q3
$11.1K Hold
3,180
– – 0.01% 357
2024
Q2
$10.4K Hold
3,180
– – 0.01% 280
2024
Q1
$23.3K Hold
3,180
– – 0.02% 162
2023
Q4
$11.9K Buy
+3,180
New +$7.51K 0.01% 185

Other funds holding FATE

Dunhill Financial's FATE Position: Q3 2026 in Review

Dunhill Financial reduced its Fate Therapeutics (FATE) stake by 100% in Q3 2026, selling an estimated $8.22K and leaving 2 shares worth $7.54K. The position accounts for ﹤0.01% of the portfolio, ranked #658.

Dunhill Financial first reported a position in FATE in Q4 2023 and has held it in 12 quarters since. The position peaked at $23.3K in Q1 2024. 142 funds tracked by Wall St. Rank hold FATE as of Q3 2026.

  • Dunhill Financial held 2 shares of Fate Therapeutics worth $7.54K as of Q3 2026.
  • Dunhill Financial sold 3,178 Fate Therapeutics shares in Q3 2026, an estimated $8.22K.
  • Fate Therapeutics made up ﹤0.01% of Dunhill Financial's portfolio in Q3 2026, its #658 holding.
  • Dunhill Financial first reported a position in Fate Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • Dunhill Financial's Fate Therapeutics position peaked at $23.3K in Q1 2024.
  • 142 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2026.

Based on Dunhill Financial's 13F filing for Q3 2026, filed 16 Nov 2026.